← Back to PPBT filing summaryOriginal filing text · Part I
Item 11 — Quantitative and Qualitative Disclosures About Market Risk
Purple Biotech Ltd · 20-F · FY 2025 · Period ended Dec 31, 2025
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market risk is the risk of
loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our financial position, results of operations or cash flows. Our overall risk management program focuses on the unpredictability
of financial markets and seeks to minimize potential adverse effects on our financial performance.
Risk of Interest Rate Fluctuation and Credit
Exposure Risk
At present, our credit and
interest risk arise from cash and cash equivalents, deposits with banks as well as accounts receivable. A substantial portion of our
liquid instruments is invested in short-term deposits with Bank Leumi le-Israel Ltd. and Bank Mizrachi-Tefachot, major Israeli banking
institutions, as well as with Valley Bank, NY, USA.
We estimate that because
our liquid instruments are invested mainly in short-term bank deposits, the credit and interest risk associated with these balances is
immaterial. The primary objective of our investment activities is to preserve principal while maximizing the income we receive from our
investments, without significantly increasing risk and loss. Our investments are exposed to market risk due to fluctuations in interest
rates, which may affect our interest income and the fair market value of our investments. We manage this exposure by performing ongoing
evaluations of our investments.
Foreign Currency Exchange Risk
Our foreign currency exposures
give rise to market risk associated with exchange rate movements of the U.S. dollar, our functional and reporting currency, mainly against
the NIS and other currencies. Although the U.S. dollar is our functional currency and reporting currency, a portion of our expenses are
denominated in NIS. Our NIS expenses consist principally of payments to employees or service providers, rent and short-term investments
in NIS. We anticipate that a sizable portion of our expenses will continue to be denominated in currencies other than the U.S. dollar.
If the U.S. dollar fluctuates significantly against the NIS, it may have a negative impact on our results of operations. We mitigate
our foreign exchange risk by aligning the currencies of our short-term investments with the currencies of anticipated expenses, based
on our expected cash flows. Furthermore, we manage this risk by hedging our monthly salary expenses that are denominated in NIS.
Portfolio diversification
is performed based on risk level limits that we set. We have in the past, and may in the future, enter into currency hedging transactions
to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures,
however, may not adequately protect us from the material adverse effects of such fluctuations.
Set forth below is a sensitivity
test to possible changes in U.S. dollars/NIS exchange rate as of December 31, 2025:
Sensitive instrument Income (loss) from change in exchange rate (U.S. dollars in thousands) Value (U.S. dollars in thousands) Income (loss) from change in exchange rate (U.S. dollars in thousands)
Down 2% Down 5% Up 2% Up 5%
Cash and cash equivalents and deposits 14 34 689 (14 ) (34 )
Other current assets 4 10 206 (4 ) (10 )
Accounts payable (3 ) (8 ) (150 ) 3 8
Other payables (22 ) (54 ) (1,078 ) 22 54
Post employment benefit liabilities (3 ) (8 ) (160 ) 3 8
Total income (loss) (10 ) (26 ) 10 26
Set forth below is a sensitivity
test to possible changes in U.S. dollars/Euro exchange rate as of December 31, 2025:
Sensitive instrument Income (loss) from change in exchange rate (U.S. dollars in thousands) Value (U.S. dollars in thousands) Income (loss) from change in exchange rate (U.S. dollars in thousands)
Down 2% Down 5% Up 2% Up 5%
Cash and cash equivalents and deposits 2 6 125 (2 ) (6 )
Accounts payable 0 0 0 0 0
Other payables 0 0 0 0 0
Total income (loss) 2 6 (2 ) (6 )
129